ARCT Stock Analysis: Arcturus Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 234m USD | 12M Return: -39.6% | US03969T1097 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.10M
Qual. Beats: 0
Rev. Trend: -87.1%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) is a clinical-stage biotechnology company headquartered in San Diego, California, founded in 2013. The company develops messenger RNA (mRNA) medicines, with a focus on therapeutics for liver and respiratory rare diseases. Its proprietary technology platforms include STARR, a self-amplifying mRNA (saRNA) platform, and LUNAR, a lipid-mediated delivery system designed to transport mRNA payloads into target cells.
Arcturuss clinical pipeline includes ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase (OTC) deficiency, both in Phase 2 development. The company is also advancing KOSTAIVE, a self-amplifying RNA COVID-19 vaccine, along with two Phase 1 influenza candidates: ARCT-2138 for seasonal influenza and ARCT-2304 for pandemic H5N1 influenza. As a micro-cap biotech, Arcturus operates within the broader mRNA therapeutics sector, an area that expanded significantly following the commercialization of COVID-19 mRNA vaccines and continues to attract investment for applications in rare diseases, infectious diseases, and protein replacement therapies.
- KOSTAIVE COVID vaccine sales from CSL partnership drive revenue
- ARCT-032 and ARCT-810 Phase 2 trial data readouts ahead
- Cash burn and potential dilution risk pressure micro-cap valuation
| Net Income: -93.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA -11.50 > 1.0 |
| NWC/Revenue: 687.5% < 20% (prev 200.5%; Δ 487.0% < -1%) |
| CFO/TA -0.32 > 3% & CFO -72.7m > Net Income -93.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.4m) vs 12m ago 4.77% < -2% |
| Gross Margin: 87.29% > 18% (prev 96.88%; Δ -9.59% > 0.5%) |
| Asset Turnover: 8.92% > 50% (prev 36.77%; Δ -27.85% > 0%) |
| Interest Coverage Ratio: -11.5k > 6 (EBIT TTM -103.1m / Interest Expense TTM 9.00k) |
| A: 0.73 (Total Current Assets 197.2m - Total Current Liabilities 33.5m) / Total Assets 224.3m |
| B: -2.52 (Retained Earnings -565.3m / Total Assets 224.3m) |
| C: -0.39 (EBIT TTM -103.1m / Avg Total Assets 266.8m) |
| D: 3.27 (Book Value of Equity 171.8m / Total Liabilities 52.5m) |
| Altman-Z'' = -2.59 = D |
| DSRI: 0.50 (Receivables 1.81m/17.2m, Revenue 23.8m/113.7m) |
| GMI: 1.11 (GM 96.88% / 87.29%) |
| AQI: 1.48 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.21 (Revenue 23.8m / 113.7m) |
| TATA: -0.09 (NI -93.3m - CFO -72.7m) / TA 224.3m) |
| Beneish M = -3.63 (Cap -4..+1) = AAA |
As of August 20, 2026, the stock is trading at USD 10.28 with a total of 5,616,094 shares traded. Over the past week, the price has changed by +35.26%, over one month by +72.19%, over three months by +53.66% and over the past year by -39.56%.
Current recommended Stop Loss: 9.70 (which is 5.6% or 1.2 ATR below the current price).
Arcturus Therapeutics has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy ARCT.
- StrongBuy: 8
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.2 | 96.5% |
P/E Forward = 2.4777
P/S = 7.9652
P/B = 1.3624
Revenue TTM = 23.8m USD
EBIT TTM = -103.1m USD
EBITDA TTM = -100.4m USD
Long Term Debt = 19.0m USD (estimated: total debt 22.9m - short term 3.97m)
Short Term Debt = 3.97m USD (from shortTermDebt, last quarter)
Debt = 22.9m USD (from shortLongTermDebtTotal, last quarter) (leases 22.9m already included)
Net Debt = -168.6m USD (calculated: Debt 22.9m - CCE 191.5m)
Enterprise Value = 65.4m USD (233.9m + Debt 22.9m - CCE 191.5m)
Interest Coverage Ratio = -11.5k (Ebit TTM -103.1m / Interest Expense TTM 9.00k)
EV/FCF = -0.89x (Enterprise Value 65.4m / FCF TTM -73.0m)
FCF Yield = -111.7% (FCF TTM -73.0m / Enterprise Value 65.4m)
FCF Margin = -306.9% (FCF TTM -73.0m / Revenue TTM 23.8m)
Net Margin = -391.9% (Net Income TTM -93.3m / Revenue TTM 23.8m)
Gross Margin = 87.29% ((Revenue TTM 23.8m - Cost of Revenue TTM 3.02m) / Revenue TTM)
Gross Margin QoQ = none% (prev -7.87%)
Tobins Q-Ratio = 0.29 (Enterprise Value 65.4m / Total Assets 224.3m)
Interest Expense / Debt = 0.04% (Interest Expense 9.00k / Debt 22.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -81.5m (EBIT -103.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.88 (Total Current Assets 197.2m / Total Current Liabilities 33.5m)
Debt / Equity = 0.13 (Debt 22.9m / totalStockholderEquity, last quarter 171.8m)
Debt / EBITDA = 1.68 (negative EBITDA) (Net Debt -168.6m / EBITDA -100.4m)
Debt / FCF = 2.31 (negative FCF - burning cash) (Net Debt -168.6m / FCF TTM -73.0m)
Total Stockholder Equity = 200.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -34.96% (Net Income -93.3m / Total Assets 224.3m)
RoE = -46.54% (Net Income TTM -93.3m / Total Stockholder Equity 200.4m)
RoCE = -47.01% (EBIT -103.1m / Capital Employed (Equity 200.4m + L.T.Debt 19.0m))
RoIC = -42.10% (negative operating profit) (NOPAT -81.5m / Invested Capital 193.6m)
WACC = 12.16% (E(233.9m)/V(256.9m) * Re(13.35%) + D(22.9m)/V(256.9m) * Rd(0.04%) * (1-Tc(0.21)))
Discount Rate = 13.35% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 83.42 | Cagr: 2.51%
[DCF] Fair Price = unknown (Cash Flow -73.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.44 | # QB: 0
Revenue Correlation: -87.12 | Revenue CAGR: -46.62% | SUE: -0.01 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.67 | Chg30d=+23.66% | Revisions=+25% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.29 | Chg30d=+14.73% | Revisions=-8% | GrowthEPS=-37.1% | GrowthRev=-77.3%
EPS next Year (2027-12-31): EPS=-3.72 | Chg30d=+7.62% | Revisions=+25% | GrowthEPS=-13.0% | GrowthRev=+58.7%
[Analyst] Revisions Ratio: +7% (up=6, down=5)